BCBrendan Collins

Brendan Collins

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Brendan Collins has a total of 207 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Digital Health in Value-Based Cardiology and EP: Evidence, Gaps and Opportunities—A Systematic Review

    by Lucía Osoro, Nikola Kozhuharov, Davide Antonio Mei, Elena Arbelo, Deirdre A Lane, Maura Zylla, Brendan Collins, Panos Vardas, Giuseppe Boriani, Joseph Figueras, et al.

    Background: Digital Health Technologies (DHTs) are increasingly embedded within VBHC frameworks to enhance outcomes and efficiency. In CV medicine, and particularly EP, they hold transformative potential through remote monitoring, AI and PROMs. Yet, evidence linking DHTs to measurable value remains fragmented Objective: To systematically assess the role of DHTs as enablers of VBHC in cardiology and EP, identifying demonstrated benefits, evidence gaps and research priorities. Methods: Following PRISMA 2020 (PROSPERO CRD420250650295), PubMed, ScienceDirect and Mendeley were searched (2017–2024) for English-language publications combining “digital health” and “value-based healthcare.” Studies meeting ≥2 criteria, VBHC focus, DHT assessment or value-oriented process analysis, were included. Data were synthesised across nine domains: electronic PROMs, mHealth, telemedicine, big data/AI and LHS. Results: Sixty-two studies and twenty-three policy documents were included. Only 4 (6.5%) were RCTs. Eighteen studies (29%) addressed CV conditions, with EP as a key focus. DHTs demonstrated value via improved adherence, earlier AF detection, HF telemonitoring and PROM integration, though few quantified cost-effectiveness or QALYs. Evidence was heterogeneous and geographically uneven. Conclusions: DHTs are pivotal enablers of value-based CV care, but robust outcome-linked evidence, especially in EP, remains limited. Wearables, telemonitoring and ePROMs illustrate measurable value, while AI-driven prediction and workflow optimisation are emerging frontiers. Future work should emphasise pragmatic trials, economic evaluations and standardised outcome metrics to reward digital value creation.

  • Open Access

    From Algorithm Development to Clinical Implementation: A Systematic Review of Artificial Intelligence in Cardiovascular Medicine

    by Lucía Osoro, Elena Arbelo, Deirdre A. Lane, Davide Antonio Mei, Nikola Kozhuharov, Maura Zylla, Brendan Collins, Panos Vardas, Giuseppe Boriani, Joseph Figueras, et al.

    Artificial intelligence (AI) is transforming cardiovascular medicine through applications in disease detection, diagnosis, risk prediction, and clinical decision support. However, the clinical implementation of these technologies remains poorly characterised. This systematic review evaluated the current landscape of AI applications in cardiovascular medicine, focusing on implementation maturity and clinical translation. The review followed PRISMA guidelines and a prospectively registered PROSPERO protocol. Data extraction included study characteristics, cardiovascular domain, AI methodology, clinical application, validation strategy and implementation maturity, assessed using a predefined five-level framework. AI methodologies were classified as conventional machine learning, deep learning, hybrid ML/deep learning, multimodal AI, or large language models/generative AI. Seventy-four studies met the eligibility criteria. Conventional machine learning was the most frequently used methodology (47.3%), followed by deep learning (41.9%), whereas multimodal AI (5.4%), hybrid ML/deep learning (2.7%), and large language models/generative AI (2.7%) were uncommon. Applications focused mainly on screening and early detection (31.1%), risk stratification and prognosis (25.7%), treatment planning (16.2%), diagnosis (13.5%), and monitoring (12.2%). Most studies reached implementation maturity Level 3 (clinical validation, 47.3%) or Level 2 (technical validation, 35.1%), while only 13.5% achieved routine clinical implementation (Level 5) and 4.1% reached clinical deployment (Level 4). Although AI demonstrated promising diagnostic and prognostic performance across multiple cardiovascular conditions, most applications remain at the validation stage. Future research should prioritise implementation science, pragmatic evaluation, and real-world evidence to facilitate routine adoption and maximise patient benefit and healthcare value.

  • Open Access

    Accounting for unmet need in equitable healthcare resource allocation: Synopsis

    by Ben Barr, Laura Anselmi, Sean Urwin, Emmanouil Mentzakis, Matthew Sutton, Shaolin Wang, Michael Anderson, Martin O’FLaherty, Christodoulos Kypridemos, Chris Bentley, et al.

    Background: The National Health Service uses formulae based on historic patterns of service use to distribute funding locally. These formulae are adjusted using avoidable mortality rates, to account for unmet needs and address health inequalities. We do not know whether this approach accurately reflects variation in unmet need between areas. Methods: We define need for National Health Service resources as the expected expenditure required to provide all standard National Health Services from which a population can benefit. We clarify the two components required to measure need: the relevant characteristics of the population living in each area and the cost weights indicating the expected needed expenditure associated with each of these characteristics. Four public advisor workshops were conducted to support the plain English description of the aims and methods used in the National Health Service resource allocation process. These led to the production of an animation to support public understanding of National Health Service resource allocation procedures. We developed four adjustments to the current National Health Service allocation formulae to better account for unmet need using electronic health records for England from 2010 and 2018 and linked primary care, hospital and mortality data from 2008 to 2020 from the Clinical Practice Research Datalink. Findings: Our responsiveness adjustment provides a method for more accurately estimating cost weights from regression models by only using data from those geographical areas that are better at aligning resources with patient need. Our longitudinal adjustment provides a new method for improving the way the utilisation formula accounts for supply-induced variation in utilisation, by using longitudinal data on people as they move between geographical areas. The primary care diagnosis adjustment shows how using linked data on primary care diagnosis improves the prediction of secondary care utilisation. Using data on people who have died from conditions, but who were not previously diagnosed, we estimate the proportion of people with 11 chronic diseases who were undiagnosed in each geographical area in England, providing an approach for adjusting National Health Service resource allocation formulae for unmet need due to underdiagnosis. Finally using instrumental variable methods we show that healthcare expenditure has larger effects on mortality in the middle deprivation groups, and smaller impacts in the top and bottom deprivation groups. These estimates indicate that some of our adjustments for unmet need may increase health inequalities. This highlights the need to maintain a ‘health inequalities adjustment’ that allocates more resources to socioeconomic groups with poor health outcomes to ensure that the National Health Service continues to help reduce health inequalities. Limitations: Limitations in the data available and a lack of coherence between adjustments for unmet need, derived from this research, indicate that a great deal of uncertainty remains. Further work is needed to enhance the availability of linked electronic health records and survey-based symptom and biomarker data to support the modelling of unmet needs. Conclusions: This programme of research has developed four adjustments targeting separate facets of unmet needs that can be implemented with the National Health Service resource allocation process as well as providing a tool that can be used to model the impact on health inequalities of any adjustment. Funding: This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health and Social Care Delivery Research programme as award number NIHR130258.

  • Open Access

    Eligibility Without Equity: Rethinking Age-Based Adult Vaccine Policies

    by Mohammed Sherif Amin, Brendan Collins, Catherine Beavis, Jennifer Sigafoos, Neil French, Daniel Hungerford

    Embedding equity into vaccine eligibility is essential for reducing health inequalities. Yet, adult vaccine eligibility in most European countries is primarily based on fixed age thresholds, prioritising cost-effectiveness. This approach risks excluding the most vulnerable populations living in deprived communities with poorer health and shorter survival into older age. Extending eligibility based on clinical risk partially addresses this gap. Higher rates of underdiagnosis and delayed diagnosis in deprived populations limit the fairness of this approach, however, with the status quo of adult vaccine eligibility criteria likely doing active harm. In this perspective, we demonstrate the extent of this inequity in England. For example, the average male living in Hyde Park in the northern city of Leeds dies 9.5 years too early to ever receive the RSV vaccine offer at age 75. Meanwhile, a male living in Hyde Park, London, lives much longer and may receive the benefits of the RSV vaccine for 10 years or more. Drawing on lessons from the COVID-19 pandemic, we propose further evaluation of alternative eligibility models that incorporate local place-based disadvantage, which will inherently account for life expectancy and deprivation levels. These models will ensure earlier access to vaccines for communities with the greatest need and improve health equity without overwhelming health systems.

  • Open Access

    Telehealth to reduce compound pressures on the National Health Service and social care: a multi-methods study protocol

    by Jennifer Downing, Rosie Kaur, Saddaf Naaz Akhtar, Elizabeth M Camacho, Konstantinos Daras, Anna Cooper, Thais Caprioli, Yuxuan Yang, Brendan Collins, Peter Almond, et al.

    Telehealth and remote monitoring are increasingly used in the management of long-term health conditions and can improve access to care. The Mersey Care Telehealth Service (MCTS) provides technology-enabled support for people with heart failure, diabetes, and chronic obstructive pulmonary disease. The service has been operating for over a decade; however, the COVID-19 pandemic has led to its rapid expansion. This study aims to gather evidence on the impact of the MCTS, explore barriers and enablers to effective service delivery and evaluate its cost-effectiveness. This study comprises of four work packages (WP). WP1: A retrospective observational analysis to evaluate whether the MCTS is associated with reduced unplanned healthcare utilisation and to examine how outcomes vary by sociodemographic characteristics and service delivery type; WP2: Longitudinal analyses to compare patient-reported outcomes, including mental health, quality of life, and wellbeing, between telehealth users and a comparator group of non-users who meet the eligibility criteria for telehealth; WP3: Remote semi-structured interviews with MCTS staff and patients will be held to explore the barriers and enablers influencing the effective service delivery; WP4: An economic evaluation will determine whether the MCTS is cost-effective compared with usual care, and will assess how cost-effectiveness varies by patient characteristics and service delivery type. This multi-method evaluation will provide robust and comprehensive evidence of the impact, equitable delivery, implementation approach, and cost-effectiveness of the MCTS. Insights seek to inform service improvement, commissioning decisions, and future telehealth strategy within the NHS.

  • Open Access

    Investigating the impact of non-pharmaceutical interventions (NPIs) on post-pandemic Respiratory Syncytial Virus (RSV) hospitalisations and seasonality in Wales, UK

    by Gabriella Santiago, Carla White, Brendan Collins, Simon Cottrell, Chris Williams, Biagio Lucini, Mike B. Gravenor


  • Open Access

    The estimated health and economic impacts of the introduction of taxation and warning labelling on foods high in fat, sugar or salt in England: A microsimulation study

    by I Gusti Ngurah Edi Putra, Brendan Collins, Zoé Colombet, Rebecca Evans, Ben Amies-Cull, Eric Robinson, Martin O’flaherty, Chris Kypridemos, Martin Enrique Flaherty

    Summary: Background: Foods high in fat, sugar, or salt (HFSS) increase risk of obesity and diet-related illnesses. Some policies, limiting HFSS placements, advertisement, and promotion, have been introduced in the UK to lower HFSS exposure, but evidence remains limited on other policy options and their potential impacts. In this study, we estimated the health and economic impacts of implementing taxation and nutrient warning (NW) labelling on HFSS products. Methods: We used the IMPACT NCD , a validated open-cohort microsimulation model, to simulate the health and economic impacts of implementing, for HFSS products, i) 8% taxation, ii) NW labelling, and iii) both combined among English adults aged 30-99 years over 15 years (2026-2040). The IMPACT NCD model utilises nationally representative surveys and routine administrative data to simulate policy and counterfactual scenarios over individuals’ life course within a competing risk framework. Based on available evidence, we estimated the policy impacts based primarily on assumed consumer-driven changes in energy and salt intake, but also examined likely reformulation in sensitivity analyses. Findings: Compared with the current counterfactual scenario (i.e., no taxation, voluntarily implemented multiple traffic light labelling), an 8% tax rate on HFSS products would reduce obesity prevalence by 2.19 percentage points [95% uncertainty intervals (UI): (1.69, 2.73)], prevent 100 000 [95% UI: (65 000, 140 000)] type 2 diabetes mellitus (T2DM), 83 000 [95% UI: (55 000, 130 000)] cardiovascular disease (CVD), 64 000 [95% UI: (48 000, 96 000)] multimorbidity or multiple long-term condition (MLTC) (i.e., Cambridge Multimorbidity Score >1.5) cases, postpone 23 000 [95% UI: (14 000, 37 000)] deaths, and save a total of £53 billion [95% UI: (41, 67)] from a societal perspective (a sum of healthcare, social care, informal care, and productivity) over 15 years. NW labelling was estimated to reduce obesity prevalence by 0.48 percentage points [95% UI: (0.20, 0.85)], prevent 26 000 [95% UI: (13 000, 52 000)] T2DM, 24 000 [95% UIs: (10 000, 41 000)] CVD, 17 000 [95% UI: (8200, 29 000)] MLTC cases, and postpone 6200 [95% UI: (2200, 12 000)] deaths, and save £14 billion [95% UIs: (6.2, 24)]. Both policies implemented together would provide greater impacts with a 2.66 percentage-point [95% UI: (2.09, 3.28)] reduction in obesity prevalence, 130 000 [95% UI: (80 000, 170 000)] T2DM, 110 000 [95% UI: (68 000, 150 000)] CVD, 81 000 [95% UI: (58 000, 110 000)] MLTC cases prevented, and 29 000 [95% UI: (18 000, 45 000)] deaths postponed, and £66 billion [95% UI: (52, 82)] saved. All modelled policies were estimated to be cost-effective and have greater health benefits for individuals in deprived groups. Sensitivity analysis involving both consumer behaviour and industry reformulation to reduce the number of products classed as HFSS yielded similar estimates. Interpretation: This is the first modelled evidence on the health and economic impacts of HFSS taxation and NW labelling. Implementing both taxation and NW labelling as additional measures to reduce HFSS consumption in the UK may provide substantial benefits in addressing obesity and diet-related diseases. Funding: National Institute for Health and Care Research Research in context: Evidence before this study: We searched modelling studies on taxation or nutrient warning (NW) labelling on products high in fat, sugar or salt (HFSS) on PubMed from 1 st January 2000 to 30 th June 2025 using the following search terms: (“food polic*“OR “fiscal polic*” OR tax* OR“label polic*” OR “nutr* label*” OR “food* label*” OR “front of pack label*” OR “front-of-pack label*” OR “warning label*”) AND (*simulation OR “model* study”) based on titles and abstracts, restricted to human subjects. We identified 241 articles. To date, no modelling studies have estimated multiple policy options, such as taxation and NW labelling on all HFSS products in the UK. A handful of studies have reported the substantial impact of taxation on sugary drinks, including in the UK, but limited studies have estimated the impact of taxation on broader unhealthy or HFSS products. One study modelled an 8% tax rate on junk food in New Zealand and reported the policy would reduce the incidence of diabetes mellitus by 7%, coronary heart disease by 3%, and the all-cause mortality rate by 1% over 30 years. Evidence from Mexico suggests greater benefit from doubling the tax rate compared to the currently implemented 8% tax rate on non-essential energy-dense foods. For NW labelling, a previous study estimated that NW labelling on all liable packaged products would reduce obesity prevalence by 2.64 percentage points and prevent 46 000 obesity-related deaths in England over 20 years, but the specific impacts of NW labelling on HFSS products, as well as the broader benefits on different health outcomes and associated economic impacts, have not yet been estimated. A study from Mexico reported that NW labelling could reduce 1.3 million obesity cases or by 4.98 percentage points in its prevalence 5 years post-implementation. Added value of this study: The present study is the first modelled evidence of the health and economic impacts of taxation (an 8% tax rate, informed by the currently implemented tax rate in Mexico) and NW labelling in England. We used the IMPACT NCD – a validated dynamic, stochastic, discrete-time, open-cohort microsimulation model with a competing risk framework at its core – to simulate the health and economic impacts of implementing, for HFSS products, i) taxation, ii) NW labelling, and iii) both combined among English adults aged from 30 to 99 years over a 15-year simulation horizon (2026-2040). We estimated the impacts on a range of health outcomes, including obesity, type 2 diabetes mellitus, cardiovascular diseases, multimorbidity or multiple long-term conditions (MLTCs), and all-cause mortality. Economic impacts were projected from healthcare (medical) and societal (medical, social care, informal care, and productivity) perspectives. We estimated that implementing both policies together would have greater impacts in addressing obesity and diet-related diseases, while also resulting in considerable economic savings. The modelled policies may reduce absolute and relative social health inequalities, as greater benefits were estimated in individuals from deprived groups. Implications of all the available evidence: The present study provides evidence to support the UK Government in considering both HFSS taxation and NW labelling as additional measures to existing policies (restrictions of HFSS placements, advertisements, and promotions) to address obesity and diet-related diseases.

  • Open Access

    Quantifying the contributions of cardiovascular risk factors to cardiovascular disease trends in 21st century Japan: a microsimulation study

    by Soshiro Ogata, Eri Kiyoshige, Yusuke Yoshikawa, Koji Iihara, Hitoshi Fukuda, Masanobu Ishii, Kenichi Tsujita, Anna Head, Brendan Collins, Martin O'FLaherty, et al.


  • Open Access

    Estimating the burden of underdiagnosis within England: A modelling study of linked primary care data

    by Olga Anosova, Anna Head, Brendan Collins, Alexandros Alexiou, Kostas Darras, Matt Sutton, Richard Cookson, Laura Anselmi, Martin O'FLaherty, Ben Barr, et al.

    Introduction: Undiagnosed chronic disease has serious health consequences, and variation in rates of underdiagnosis between populations can contribute to health inequalities. We aimed to estimate the level of undiagnosed disease of 11 common conditions and its variation across sociodemographic characteristics and regions in England. Methods: We used linked primary care, hospital and mortality data on approximately 1.3 million patients registered at a GP practice for more than one year from 01/04/2008–31/03/2020 from Clinical Practice Research Datalink. We created a dynamic state model with six states based on the diagnosis and mortality of 11 conditions: coronary heart disease (CHD), stroke, hypertension, chronic obstructive pulmonary disease, type 2 diabetes, dementia, breast cancer, prostate cancer, lung cancer, colorectal cancer, and depression/anxiety. Undiagnosed disease was conceptualised as those who died with a condition but were not previously diagnosed. This was combined with observed data on the incidence of diagnosis, the case fatality rate in the diagnosed, and an assumption about how that rate varies with diagnosis to estimate the number of undiagnosed disease cases over the total number of disease cases (underdiagnosis) in each population group. We estimated underdiagnosis by year, sex, 10-year age group, relative deprivation, and administrative region. We then applied small-area estimation techniques to derive underdiagnosis estimates for health planning areas (CCGs). Results: Levels of underdiagnosis varied between 16% for stroke and 69% for prostate cancer in 2018. For all diseases, the level of underdiagnosis declined over time. Underdiagnosis was not consistently concentrated in areas with high deprivation. For depression/anxiety and stroke, underdiagnosis was estimated to be higher in less deprived CCGs, whilst for CHD and T2DM, it was estimated to be higher in more deprived CCGs, with no apparent relationships for other conditions. We found no uniform spatial patterns of underdiagnosis across all diseases, and the relationship between age, deprivation and the probability of being undiagnosed varied greatly between diseases. Discussion: Our findings suggest that underdiagnosis is not consistently concentrated in areas with high deprivation, nor is there a uniform spatial underdiagnosis pattern across diseases. This novel method for estimating the burden of underdiagnosis within England depends on the quality of routinely collected data, but it suggests that more research is needed to understand the key drivers of underdiagnosis.